AAM
SAGE

Azzad Asset Management’s Sage Therapeutics SAGE Stock Holding History

Azzad Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,246
Closed -$242K – 339
2019
Q4 		$242K Hold
4,246
– – 0.03% 346
2019
Q3 		$386K Buy
4,246
+1,239
+41% +$207K 0.05% 318
2019
Q2 		$551K Hold
3,007
– – 0.15% 216
2019
Q1 		$478K Buy
+3,007
New +$435K 0.14% 229
2018
Q4 		– Sell
-2,006
Closed -$283K – 317
2018
Q3 		$283K Buy
+2,006
New +$310K 0.08% 304

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Azzad Asset Management's SAGE Position: Q1 2020 in Review

Azzad Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 4,246 shares — an estimated $242K sold.

Azzad Asset Management first reported a position in SAGE in Q3 2018 and held it in 5 quarters. The position peaked at $551K in Q2 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Azzad Asset Management reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Azzad Asset Management sold 4,246 Sage Therapeutics shares in Q1 2020, an estimated $242K.
  • Azzad Asset Management first reported a position in Sage Therapeutics in Q3 2018 and held it in 5 quarters.
  • Azzad Asset Management's Sage Therapeutics position peaked at $551K in Q2 2019.
  • 229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Azzad Asset Management's 13F filing for Q1 2020, filed 1 Apr 2024.